Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.

Antimicrobial agents and chemotherapy - 1 Oct 2015

Chou Sunwen

Abstract excerpt

Letermovir (LMV) is an experimental cytomegalovirus terminase inhibitor undergoing phase 3 clinical trials. Viral mutations have been described at UL56 codons 231 to 369 that confer widely variable levels of LMV resistance. In this study, 15 independent experiments propagating an exonuclease mutant viral strain in escalating LMV concentrations replicated 6 of the 7 published UL56 mutations and commonly elicited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetates
Share to Antiviral Agents
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytomegalovirus and herpesvirus research

Share to Herpesvirus Infections and Treatments

Share to Mutation

Share to Quinazolines

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 26259791
DOI: 10.1128/AAC.01623-15
PMCID: PMC4576131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.PMID 26259791Read ↗

New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir.Semantic proximity Read ↗

A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.Semantic proximity Read ↗

Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing.Semantic proximity Read ↗

De Novo Genotypic Heterogeneity in the UL56 Region in Cytomegalovirus-Infected Tissues: Implications for Primary Letermovir Resistance.Semantic proximity Read ↗

Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds.Semantic proximity Read ↗

Competitive Fitness of Cytomegalovirus Mutants Bearing Changes in the UL56 Terminase Subunit, Associated with Letermovir-Resistance, in Presence and Absence of Antivirals.Semantic proximity Read ↗

First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.Semantic proximity Read ↗

Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes.Semantic proximity Read ↗

Drug-resistant cytomegalovirus: clinical implications of specific mutations.Semantic proximity Read ↗

In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene productsSemantic proximity Read ↗

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.Semantic proximity Read ↗

Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.